Race-specific molecular alterations correlate with differential outcomes for black and white endometrioid endometrial cancer patients

Cancer

Volumn 123, Issue 20, 2017, Pages 4004-4012

  Bateman, Nicholas W ^a   Dubil, Elizabeth A ^a   Wang, Guisong ^a   Hood, Brian L ^a   Oliver, Julie M ^a   Litzi, Tracy A ^a   Gist, Glenn D ^a   Mitchell, David A ^a   Blanton, Brian ^a   Phippen, Neil T ^a   Tian, Chunqiao ^a   Zahn, Christopher M ^b   Cohn, David E ^c   Havrilesky, Laura J ^d   Berchuck, Andrew ^d   Shriver, Craig D ^a   Darcy, Kathleen M ^a   Hamilton, Chad A ^a   Conrads, Thomas P ^a,e   Maxwell, G Larry ^a,e,f  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e Inova Schar Cancer Institute   (United States)

^f Inova Fairfax Medical Campus ^*  (United States)

Author keywords

endometrioid endometrial cancer; overall survival; progression free survival; proteomics; racial disparity; RNA seq

Indexed keywords

ABCA5 GENE; AFRICAN AMERICAN; AP4S1 GENE; ARTICLE; BET1L GENE; C19ORF25 GENE; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CAPN6 GENE; CAUCASIAN; CELL DEATH; CELL VIABILITY; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DAP GENE; DSN1 GENE; ENDOMETRIOID ENDOMETRIAL CANCER; ENDOMETRIUM CANCER; EPM2A GENE; FAM228B GENE; FEMALE; GENE; HEATR6 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; ITGA3 GENE; LIG3 GENE; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MALL GENE; MYOMETRIAL INVASION; OVERALL SURVIVAL; PBX1 GENE; PNPT1 GENE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PSMD5 AS1 GENE; RNA SEQUENCE; SERPINA4 GENE; SLC24A1 GENE; TUMOR INVASION; UCP2 GENE; WDR97 GENE; WTAP GENE; DISEASE FREE SURVIVAL; ENDOMETRIOID CARCINOMA; ENDOMETRIUM TUMOR; ETHNOLOGY; GENE EXPRESSION PROFILING; GENETICS; HEALTH DISPARITY; LIQUID CHROMATOGRAPHY; METABOLISM; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TANDEM MASS SPECTROMETRY;

ALPHA3 INTEGRIN; BET1L PROTEIN, HUMAN; ITGA3 PROTEIN, HUMAN; KALLISTATIN; MEMBRANE PROTEIN; QC SNARE PROTEIN; SERINE PROTEINASE INHIBITOR;

AFRICAN AMERICANS; CARCINOMA, ENDOMETRIOID; CHROMATOGRAPHY, LIQUID; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE EXPRESSION PROFILING; HEALTH STATUS DISPARITIES; HUMANS; INTEGRIN ALPHA3; MEMBRANE PROTEINS; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; QC-SNARE PROTEINS; SERPINS; TANDEM MASS SPECTROMETRY;

EID: 85021352774     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30813     Document Type: Article

References (27)

1. Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66:271-289.
2. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2013. Bethesda, MD: National Cancer Institute; 2016.
3. Hicks ML, Phillips JL, Parham G, et al. The National Cancer Data Base report on endometrial carcinoma in African-American women. Cancer. 1998;83:2629-2637.
4. Ghafoor A, Jemal A, Cokkinides V, et al. Cancer statistics for African Americans. CA Cancer J Clin. 2002;52:326-341.
5. Maxwell GL, Risinger JI. Racial disparities research: it's not just black and white. Gynecol Oncol. 2006;101:194-197.
6. Oliver KE, Enewold LR, Zhu K, et al. Racial disparities in histopathologic characteristics of uterine cancer are present in older, not younger blacks in an equal-access environment. Gynecol Oncol. 2011;123:76-81.
7. Maxwell GL, Tian C, Risinger J, et al. Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma. A Gynecologic Oncology Group study. Cancer. 2006;107:2197-2205.
8. Kohler MF, Carney P, Dodge R, et al. p53 overexpression in advanced-stage endometrial adenocarcinoma. Am J Obstet Gynecol. 1996;175:1246-1252.
9. Maxwell GL, Risinger JI, Hayes KA, et al. Racial disparity in the frequency of PTEN mutations, but not microsatellite instability, in advanced endometrial cancers. Clin Cancer Res. 2000;6:2999-3005.
10. Santin AD, Bellone S, Siegel ER, et al. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. Am J Obstet Gynecol. 2005;192:813-818.
11. Maxwell GL, Allard J, Gadisetti CV, et al. Transcript expression in endometrial cancers from black and white patients. Gynecol Oncol. 2013;130:169-173.
12. Maxwell GL, Shoji Y, Darcy K, et al. MicroRNAs in endometrial cancers from black and white patients. Am J Obstet Gynecol. 2015;212:191.e1-191.e10.
13. Gaber C, Meza R, Ruterbusch JJ, Cote ML. Endometrial cancer trends by race and histology in the USA: projecting the number of new cases from 2015 to 2040. J Racial Ethn Health Disparities. In press.
14. Kandoth C, Schultz N, Cherniack AD, et al; Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67-73.
15. Hood BL, Liu B, Alkhas A, et al. Proteomics of the human endometrial glandular epithelium and stroma from the proliferative and secretory phases of the menstrual cycle. Biol Reprod. 2015;92:106.
16. Broad Institute. Index of /runs/stddata__2015_11_01/data/UCEC/20151101. http://gdac.broadinstitute.org/runs/stddata__2015_11_01/data/UCEC/20151101.
17. Kramer A, Green J, Pollard J Jr, Tugendreich S. Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics. 2014;30:523-530.
18. Cooksley-Decasper S, Reiser H, Thommen DS, et al. Antibody phage display assisted identification of junction plakoglobin as a potential biomarker for atherosclerosis. PLoS One. 2012;7:e47985.
19. Menon R, Omenn GS. Proteomic characterization of novel alternative splice variant proteins in human epidermal growth factor receptor 2/neu-induced breast cancers. Cancer Res. 2010;70:3440-3449.
20. Miao RQ, Agata J, Chao L, Chao J. Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood. 2002;100:3245-3252.
21. Sun HM, Mi YS, Yu FD, et al. SERPINA4 is a novel independent prognostic indicator and a potential therapeutic target for colorectal cancer. Am J Cancer Res. 2016;6:1636-1649.
22. Zhi X, Lin L, Yang S, et al. βII-Spectrin (SPTBN1) suppresses progression of hepatocellular carcinoma and Wnt signaling by regulation of Wnt inhibitor kallistatin. Hepatology. 2015;61:598-612.
23. Xu Y, Wong SH, Zhang T, Subramaniam VN, Hong W. GS15, a 15-kilodalton Golgi soluble N-ethylmaleimide–sensitive factor attachment protein receptor (SNARE) homologous to rbet1. J Biol Chem. 1997;272:20162-20166.
24. Edwards TL, Hartmann KE, Velez Edwards DR. Variants in BET1L and TNRC6B associate with increasing fibroid volume and fibroid type among European Americans. Hum Genet. 2013;132:1361-1369.
25. Edwards TL, Michels KA, Hartmann KE, Velez Edwards DR. BET1L and TNRC6B associate with uterine fibroid risk among European Americans. Hum Genet. 2013;132:943-953.
26. Sharma S, Javadekar SM, Pandey M, Srivastava M, Kumari R, Raghavan SC. Homology and enzymatic requirements of microhomology-dependent alternative end joining. Cell Death Dis. 2015;6:e1697.
27. Rocconi RP, Lankes HA, Brady WE, et al. The role of racial genetic admixture with endometrial cancer outcomes: an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2016;140:264-269.